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Abstract
A case of a 66-years-old male with iron deficiency anemia for more than 16 years, refractory to management
with iron therapy is reported. Fecal occult blood test done several times was found to be negative. Upper and
lower endoscopy revealed no source of bleeding. Capsule enterscopy showed no vascular malformations in
the jejunum and ileum. The patient was managed with repeated blood transfusions. Abdominal ultrasound
followed by CT scan abdomen revealed right renal soft tissue lesion. A CT-guided biopsy was then taken;
the histopathology revealed a clear cell renal cell carcinoma. Right radical nephrectomy was done; the
patient’s hemoglobin showed a dramatic increase to 14 g/dL within one month. The dramatic response of
the anemia to surgery mandates considering renal cell carcinoma in the workup of the possible causes of
iron deficiency anemia. Only one similar case has been previously reported.
© 2013 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. 
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Renal cell carcinoma (RCC) is the most common type of kidney can-
cer in adults and represents approximately 80% of renal neoplasms
[1]. It is described as being among the most lethal of all the urological
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Open access under CC BY-NC-ND license.ancers [2]. It is a collection of different types of neoplasms, each
erived from the various parts of the nephron (epithelium or renal
ubules) and possessing distinct genetic characteristics, histological
eatures, and to some extent, clinical phenotypes [9]. Historically,
edical practitioners expected a person to present with classic triad
3] is hematuria, flank pain, and an abdominal mass, similar to bloat-
ng but larger. It is now known that this classic triad of symptoms
nly occurs in 10–15% of cases, and is usually indicative that RCC
s in an advanced stage [3]. Other signs and symptom may include
4]; malaise, weight loss and/or loss of appetite, erythrocytosis due
o increased erythropoietin secretion [4], varicocele, which is seen
n males as an enlargement of the tissue at the testicle (more often
he left testicle) [4] hypertension resulting from secretion of renin
y the tumor [5]; hypercalcemia, which is [6]; sleep disturbance or
 license.ight sweats [7]; recurrent fevers [7]; and chronic fatigue [8], ane-
ia resulting from depression of erythropoietin [4]. Today, RCC is
ften asymptomatic (meaning little to no symptoms) and is gener-
lly detected incidentally when a person is being examined for other
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ilments [4]. Although association with anemia is reported in one
hird of patients with renal cell carcinoma. Initial treatment is most
ommonly a radical or partial nephrectomy and remains the main-
tay of curative treatment [10]. Considering the paucity of data in
he literature concerning the rare presentation with iron deficiency
nemia, we reported our experience with a patient diagnosed as renal
ell carcinoma, incidentally after long journey of iron therapy.
ase  report
 66 years old male who is a known case of type-II diabetes diag-
osed in 1999 as reported. He is on regular treatment with metformin
50 mg twice daily and Gliz 2 mg per day. The patient gave his-
ory of recurrent anemia since 1962, which was diagnosed as iron
eficiency anemia based on complete blood count, serum iron and
erritin plus TIBC. The patient did not bleed from any site and was
n good nutritional status. Different diagnostic tools were included:
tool for occult blood was negative. Upper and lower GIT endoscopy
evealed normal findings. The patient developed dyspnea on mild
xcretion in addition to signs of impeding heart failure, mild hep-
tomegally with raised JVP and hemic murmur. Therefore, he had
o have packed red blood cells transfused.
n 2012, 10th of March the patient presented to the outpatient
linic with fatigability and dyspnea during exertion associated with
alpitation. There was no history of cough, but there were syn-
opal attacks that developed three times before he sought medical
dvice. CBC was done; results showed Hb 6.9 g/dL, RBC 2.82, HCT
3.6%, MCV 83.7 fL, MCH 24.5 pg, MCHC 29.2 g/dL, platelets
63 ×  109/L with TWBC 7.8 ×  109/L and RDW (CV) 19.5. Serum
ron and ferritin were extremely low (3.1 and 2, respectively). TIBC
as 674 g/dL. Stool for occult blood was initially positive. Repeated
nalysis after withdrawal of ferrous supplement for 3 days yielded
egative results. Abdominal scan was requested and a gastroen-
erology physician was consulted. He did upper and lower GIT
ndoscopy, a well defined ovoid shaped soft tissue mass in the
ight kidney implicating its anterior aspect, measuring 62 ×  48 mm
ith faint arterial enhancement. No calcification was detected and
xcretory function was adequate. The left kidney was unremark-
ble. Renal function tests were normal and there was no microscopic
ematuria. A CT guided biopsy of the mass was requested. Biopsy
esult showed a renal cell carcinoma consisting of polygonal cells
ith clear cytoplasm and centrally located nuclei interspersed by
lood vessels with hemosiderin laden macrophages (Fig. 1), which
ndicate that this tumor is a classic (clear cell) renal cell carcinoma
ith abundant iron within the tumor, which could be explained by
he tumor eating the iron. The patient was referred to the urology
epartment, after correction of the anemia with 4 units of packed red
lood cells. Nephrectomy done and his Hb monitored on monthly
asis.
iscussion
he usual clinical presentation of renal cell carcinoma is triad of
ymptoms of hematuria, flank pain, and an abdominal mass 10–15%
f cases [3]. Although anemia was described in one third of patients
ith renal cell carcinoma, the majority of cases are anemia ofhronic disorder due to depression of erythropoietin production.
nteresting in this case is that the patient has been treated in hematol-
gy department for more than 16 years as a case of iron deficiency
nemia refractory to management. Since the only symptoms and
o
n
d
cigure  1  Tumor with Perl’s stain showing hemosiderin laden
acrophages with abundant iron deposition.
igns is related to anemia, which was confirmed by low Hb with
he combination of low MCV, MCH and high RDW with peripheral
lood picture of microcytic hypochromic anemia, that is commonly
een in the differential diagnosis of iron deficiency anemia, tha-
assaemia, sideroblastic anemia, and anemia of chronic disorder.
ur patient is an elderly patient and the condition started 1962 with
eatures of anemia, worsening when he stopped using iron supple-
ent. This feature excludes thalassemia as a cause. On the contrary,
here was no history of repeated transfusions or exposure to toxin and
o basophilic stippling noted in the peripheral blood film, findings
hich exclude thalasaemia and sideroblastic anemia. The diagno-
is of iron deficiency anemia was confirmed by increased TIB, low
erum iron and ferritin. Searching for an underlying cause in this
ype of anemia is the core for appropriate management, because
ngoing losses or failure to alleviate the underlying cause will lead to
efractory iron deficiency anemia and will worsen the situation. The
ommonest cause for iron deficiency anemia among this age group
s chronic blood loss, followed by nutritional causes, and ingestion
f drugs such as ibuprofen, aspirin or anti-acids. The screening for a
ource of bleeding showed stools to be negative for occult blood with
ormal OGD. Capsule enterscopy was normal. CEA and CA19-9
ere negative. There was no evidence of colonic or gastric carci-
oma or hemorrhoids. The patient was nutritionally supported and
here was no history ingestion of aspirin, ibuprofen or anti acid.
t is unusual for iron deficiency anemia to be the presenting feature
f renal cell carcinoma as it is the case in our patient for whom
bdominal ultrasound revealed a renal mass for histopathological
orrelation. Computed tomography guided biopsy was done showed
 clear renal cell carcinoma. To the best of our knowledge, only one
imilar case has been previously reported in 1984 by Kroll et al.
11].
onclusion
here is a variant of clear renal cell carcinoma which is associ-
ted with consumption of iron. Whether this finding is accidental
r related to the pathophysiology of the renal cell carcinoma, it
eeds to be elucidated. Hence iron stain (Perl’s stain) should be
one for clear renal cell carcinoma. Investigating causes of iron defi-
iency anemia are not complete without imaging of internal organs
[Renal cell carcinoma 
(kidneys). Nephrectomy might be the sole answer for the manage-
ment of iron deficiency anemia due to renal cell carcinoma.
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